Moderna vaccine progress a 'positive development' according to former FDA commissioner, but 'there's a lot of work ahead'


Early data on a coronavirus vaccine candidate is encouraging, but there's still "a lot of work" to be done, the former commissioner of the FDA says.
Moderna on Monday announced some "positive" interim data on its potential COVID-19 vaccine, saying that eight patients in a phase one trial developed antibodies at levels similar to those who recovered from the coronavirus. The stock market surged in reaction to the hope that a vaccine could be on the horizon.
Scott Gottlieb, former Food and Drug Administration commissioner, in an interview on CNBC Tuesday agreed this was a "positive development," since it suggests the vaccine "can produce an immune response." He noted, though, that since Moderna only tested the first eight patients of 45 for neutralizing antibodies, "we need to know the data on the other patients, and whether in fact those are neutralizing antibodies, the kinds of antibodies that target the virus and destroy the virus."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
"They need to figure out what the right dose is for this vaccine, so they're going to need to do a lot of phase two work before they can get into a phase three trial to determine the optimal dose," Gottlieb said. "We also have to make sure that these vaccines are producing neutralizing antibodies."
Based on early data, it now seems "reasonable" to assume we'll get a vaccine against COVID-19 "at some point," Gottlieb concluded. But when? Though President Trump has touted a potential end-of-year timeline, Gottlieb, who previously said a widely-available vaccine is likely a "2021 event," isn't sure about this incredibly tight schedule.
"The timing is questionable," he said, "whether or not we can have it before the end of the year, or whether or not we'll have to wait until 2021 to have a product we can use more generally." Brendan Morrow
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Brendan worked as a culture writer at The Week from 2018 to 2023, covering the entertainment industry, including film reviews, television recaps, awards season, the box office, major movie franchises and Hollywood gossip. He has written about film and television for outlets including Bloody Disgusting, Showbiz Cheat Sheet, Heavy and The Celebrity Cafe.
-
'Wonder drug': the potential health benefits of creatine
The Explainer Popular fitness supplement shows promise in easing symptoms of everything from depression to menopause and could even help prevent Alzheimer's
-
What's next for Elon Musk?
Today's Big Question The world's richest man has become 'disillusioned' with politics – but returning to his tech empire presents its own challenges
-
Quiz of The Week: 24 – 30 May
Have you been paying attention to The Week's news?
-
RFK Jr. scraps Covid shots for pregnant women, kids
Speed Read The Health Secretary announced a policy change without informing CDC officials
-
New FDA chiefs limit Covid-19 shots to elderly, sick
speed read The FDA set stricter approval standards for booster shots
-
US overdose deaths plunged 27% last year
speed read Drug overdose still 'remains the leading cause of death for Americans aged 18-44,' said the CDC
-
Trump seeks to cut drug prices via executive order
speed read The president's order tells pharmaceutical companies to lower prescription drug prices, but it will likely be thrown out by the courts
-
RFK Jr. visits Texas as 2nd child dies from measles
Speed Read An outbreak of the vaccine-preventable disease continues to grow following a decade of no recorded US measles deaths
-
Shingles vaccine cuts dementia risk, study finds
Speed Read Getting vaccinated appears to significantly reduce the chances of developing Alzheimer's and other forms of dementia
-
Measles outbreak spreads, as does RFK Jr.'s influence
Speed Read The outbreak centered in Texas has grown to at least three states and Health Secretary Robert F. Kennedy Jr. is promoting unproven treatments
-
RFK Jr. offers alternative remedies as measles spreads
Speed Read Health secretary Robert F. Kennedy Jr. makes unsupported claims about containing the spread as vaccine skepticism grows